Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer (Q73274545)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10598924%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10598924%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

non-small-cell lung carcinoma

1 reference

1 reference

T Yano

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10598924%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

K Sugio

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10598924%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

K Yamazaki

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10598924%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

S Kase

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10598924%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

M Yamaguchi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10598924%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

K Ondo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10598924%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

I Yoshino

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10598924%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

K Sugimachi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10598924%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 December 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10598924%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10598924%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10598924%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10598924%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

143-148

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10598924%20AND%20SRC:MED&resulttype=core&format=json

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900082-3

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900082-3

7 January 2021

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900082-3

7 January 2021

Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900082-3

7 January 2021

A Phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900082-3

7 January 2021

A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900082-3

7 January 2021

A regimen of surgical adjuvant immunotherapy for cancer with interleukin 2 and lymphokine-activated killer cells. Basis, clinical toxicity, and immunomodulatory effects

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900082-3

7 January 2021

Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900082-3

7 January 2021

An enzyme-immunoassay for human interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900082-3

7 January 2021

Generation and expansion of lymphokine-activated killer cells from lymph node lymphocytes in human lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900082-3

7 January 2021

Development of a new culture system for human lymphokine-activated killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900082-3

7 January 2021

Phenotypic characterization of lymphokine-activated killer cells from human lymph node lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900082-3

7 January 2021

10.1016/S0169-5002(99)00082-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10598924%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference